Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 2, 2026, 10:07 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 354 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Electrocardiography Clear all
Recruiting No phase listed Observational

Deep Learning Detection of Pulmonary Hypertension and Low Ejection Fraction Via Digital Stethoscope and 3-Lead ECG

NCT07087613
View directory record Official record
Conditions
Hypertension, Pulmonary, Heart Failure With Reduced Ejection Fraction
Interventions
Eko CORE 500 Digital Stethoscope
Device
Lead sponsor
Eko Devices, Inc.
Industry
Eligibility
18 Years and older
Enrollment
3,850 participants
Timeline
2025 – 2027
U.S. locations
4
States / cities
O'Fallon, Illinois • Springfield, Illinois • Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Sep 2, 2026, 10:07 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Influence of Testosterone Administration on Drug-Induced QT Interval Prolongation and Torsades de Pointes

NCT02513940
View directory record Official record
Conditions
Long QT Syndrome
Interventions
Testosterone, Progesterone, Placebo, Ibutilide
Drug
Lead sponsor
Indiana University
Other
Eligibility
65 Years and older · Male only
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Aug 27, 2019 · Synced Sep 2, 2026, 10:07 AM EDT
Completed No phase listed Observational

Surface Electrocardiogram (ECG) Signal Recording for Implantable Subcutaneous String Defibrillator (ISSD) Development

NCT02991716
View directory record Official record
Conditions
Arrhythmia, Cardiac
Interventions
recorded patients
Other
Lead sponsor
NewPace Ltd
Industry
Eligibility
Not listed
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Atlantis, Florida
Source: ClinicalTrials.gov public record
Updated Jan 16, 2018 · Synced Sep 2, 2026, 10:07 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Pulse Oximeter Validation Study for the Perin Health Patch

NCT07027150
View directory record Official record
Conditions
Hypoxia
Interventions
Chest Worn Pulse Oximeter
Device
Lead sponsor
Perin Health Devices
Industry
Eligibility
18 Years to 50 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 17, 2025 · Synced Sep 2, 2026, 10:07 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Dozee Validation for Contactless Heart Rate and Respiration Monitoring in Clinical Settings

NCT07735403
View directory record Official record
Conditions
No Specific Medical Conditions or Disease States
Interventions
Telemetry monitoring
Device
Lead sponsor
Turtle Shell Technologies Pvt. Ltd.
Industry
Eligibility
22 Years to 100 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Lake Jackson, Texas
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Sep 2, 2026, 10:07 AM EDT
Completed Phase 3 Interventional

Risk Score Alerts for Chest Pain Care

NCT00674375
View directory record Official record
Conditions
Chest Pain, Acute Myocardial Infarction
Interventions
Electronic risk alerts
Other
Lead sponsor
Harvard Vanguard Medical Associates
Other
Eligibility
30 Years and older
Enrollment
8,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
2
States / cities
Boston, Massachusetts • Newton, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 17, 2015 · Synced Sep 2, 2026, 10:07 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess Electrocardiogram Results in Healthy Volunteers Receiving Canagliflozin (JNJ-28431754)

NCT01787357
View directory record Official record
Conditions
Healthy
Interventions
Canagliflozin (JNJ-28431754), Placebo, Moxifloxacin
Drug
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Industry
Eligibility
18 Years to 55 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Jun 28, 2016 · Synced Sep 2, 2026, 10:07 AM EDT
Completed Not applicable Interventional

The Influence of Cardiorespiratory Fitness on Firefighter Cardiovascular Health Under Exercise Conditions

NCT04514354
View directory record Official record
Conditions
Cardiovascular Diseases, Post-Exercise Hypotension
Interventions
GEST
Behavioral
Lead sponsor
University of Connecticut
Other
Eligibility
21 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Hartford, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 13, 2020 · Synced Sep 2, 2026, 10:07 AM EDT
Completed No phase listed Observational

Smartphone Twelve Lead Electrocardiogram Utility In ST-Elevation Myocardial Infarction

NCT03037229
View directory record Official record
Conditions
STEMI
Interventions
Smartphone ECG, Standard 12-lead ECG
Device
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 6, 2018 · Synced Sep 2, 2026, 10:07 AM EDT
Completed Not applicable Interventional

Biofeedback-VR for Treatment of Chronic Migraine

NCT05720819
View directory record Official record
Conditions
Chronic Migraine, Behavioral Treatment, Biofeedback, Virtual Reality, Medication Overuse Headache
Interventions
Combined biofeedback-virtual reality device
Device
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 85 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Feb 8, 2023 · Synced Sep 2, 2026, 10:07 AM EDT
Completed Phase 2 Interventional Results available

Superenhancer Inhibitor Minnelide in Advanced Refractory Adenosquamous Carcinoma of the Pancreas (ASCP)

NCT04896073
View directory record Official record
Conditions
Adenosquamous Carcinoma of the Pancreas
Interventions
Minnelide, ECG, CT/MRI, Tumor Biopsy
Drug · Diagnostic Test · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Sep 2, 2026, 10:07 AM EDT
Recruiting No phase listed Observational

Ultra-High Frequency - Electrocardiogram (UHF-ECG) for the Diagnosis of Ventricular Electrical Dyssynchrony (VED)

NCT06641362
View directory record Official record
Conditions
Bradycardia, Heart Failure, Ventricular Dysfunction
Interventions
Ultra High Frequency Electrocardiogram (UHF-ECG)
Device
Lead sponsor
VDI Technologies
Industry
Eligibility
18 Years and older
Enrollment
360 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
7
States / cities
Avondale, Arizona • Mesa, Arizona • Chicago, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Sep 2, 2026, 10:07 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional Results available

Lenalidomide Combined With Modified DA-EPOCH and Rituximab (EPOCH-R2) in Primary Effusion Lymphoma or KSHV-associated Large Cell Lymphoma

NCT02911142
View directory record Official record
Conditions
Primary Effusion Lymphoma, B-Cell Neoplasm
Interventions
Lenalidomide, Rituximab, Prednisone, Etoposide, Doxorubicin, Vincristine, Cyclophosphamide, CT of neck, chest, abdomen and pelvis, 18FDG-PET scan, MRI Brain, Bone marrow biopsy, EKG, Echocardiogram, Ultrasound, Bronchoscopy, Endoscopy, CXR: PA/lat/decub
Drug · Diagnostic Test · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2028
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Sep 2, 2026, 10:07 AM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Detection and Classification of Cardiac Rhythm and Atrial Fibrillation Using a Finger-worn Ring

NCT06892938
View directory record Official record
Conditions
Atrial Fibrillation (AF), Arrhythmias Cardiac, Tachycardia, Palpitations, Bradycardia
Interventions
Atrial Fibrillation Identification
Diagnostic Test
Lead sponsor
Everbeat
Industry
Eligibility
18 Years and older
Enrollment
232 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
3
States / cities
La Jolla, California • Baton Rouge, Louisiana • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 26, 2025 · Synced Sep 2, 2026, 10:07 AM EDT
Completed No phase listed Observational

Extended ECG Monitoring in HCM Patients

NCT04056715
View directory record Official record
Conditions
Hypertrophic Cardiomyopathy, Nonsustained Ventricular Tachycardia, Ventricular Tachycardia, Atrial Fibrillation, Arrhythmia
Interventions
Zio XT
Device
Lead sponsor
iRhythm Technologies, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 28, 2023 · Synced Sep 2, 2026, 10:07 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Study to Evaluate the Effect of Ha44 Gel on the Electrocardiogram in Healthy Volunteers

NCT01518699
View directory record Official record
Conditions
Pediculosis
Interventions
Ha44, Ha44 Placebo, Moxifloxacin Placebo, Moxifloxacin
Drug
Lead sponsor
Dr. Reddy's Laboratories Limited
Industry
Eligibility
18 Years to 50 Years
Enrollment
57 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
West Bend, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jul 8, 2021 · Synced Sep 2, 2026, 10:07 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Trial of EP0057, a Nanoparticle Camptothecin With Olaparib in People With Relapsed/Refractory Small Cell Lung Cancer

NCT02769962
View directory record Official record
Conditions
Urothelial Carcinoma, Urothelial Cancer, Lung Neoplasms, Small Cell Lung Cancer, Prostate Cancer
Interventions
EP0057, olaparib, CT scan, CT chest, abdomen, and pelvis, Bone scan, ECG, Echocardiogram, Biopsy
Drug · Diagnostic Test · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2025
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Sep 2, 2026, 10:07 AM EDT
Completed Phase 1 Interventional Results available

Romidepsin, CC-486 (5-azacitidine), Dexamethasone, and Lenalidomide (RAdR) for Relapsed/Refractory T-cell Malignancies

NCT04447027
View directory record Official record
Conditions
Cutaneous T-Cell Lymphoma, Mature T-cell Malignancies, Peripheral T-Cell Lymphoma, Relapsed/ Refractory T-cell Malignancies
Interventions
Romidepsin, Lenalidomide, CC-486 (5-azacitidine), Dexamethasone, EKG, Bone Marrow Aspiration/Biopsy, MRI, Lumbar Puncture, TTE
Drug · Diagnostic Test · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Sep 2, 2026, 10:07 AM EDT
Completed No phase listed Observational

Prognostic Significance of T Wave Alternans

NCT00006501
View directory record Official record
Conditions
Heart Diseases, Ventricular Arrhythmia, Ventricular Fibrillation, Death, Sudden, Cardiac, Heart Arrest
Interventions
ECG
Procedure
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
549 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2012
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 22, 2015 · Synced Sep 2, 2026, 10:07 AM EDT
Completed Phase 1 Interventional

A Cardiac Safety Study of Tivozanib to Evaluate the Electrocardiogram and Pharmacokinetic-Electrocardiogram Dynamics in Subjects With Advanced Solid Tumors

NCT01210846
View directory record Official record
Conditions
Advanced Solid Tumors
Interventions
tivozanib
Drug
Lead sponsor
AVEO Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
8
States / cities
Scottsdale, Arizona • Fort Myers, Florida • Lafayette, Indiana + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2011 · Synced Sep 2, 2026, 10:07 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Thorough QT Study of TR-701free Acid (FA) in Healthy Subjects

NCT01461460
View directory record Official record
Conditions
Healthy Volunteer
Interventions
TR-701 FA 1200 mg, Moxifloxacin 400 mg, TR-701 FA 200 mg plus Placebo, Placebo
Drug
Lead sponsor
Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years to 45 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Dec 4, 2018 · Synced Sep 2, 2026, 10:07 AM EDT
Completed Phase 4 Interventional

Metformin as an Adjunctive Therapy to Catheter Ablation in Atrial Fibrillation

NCT04625946
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
Metformin, Recommendations for lifestyle modification., AliveCor
Drug · Behavioral · Device
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
117 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Sep 28, 2025 · Synced Sep 2, 2026, 10:07 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Evaluation of the Performance and Safety of the Aktiia Spot-check Optical Blood Pressure Monitoring Device At Wrist Against Double Auscultation

NCT06565780
View directory record Official record
Conditions
Hypertension
Interventions
Device under test evaluation against references
Device
Lead sponsor
Aktiia SA
Industry
Eligibility
22 Years to 59 Years
Enrollment
140 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Broomfield, Colorado
Source: ClinicalTrials.gov public record
Updated Feb 17, 2025 · Synced Sep 2, 2026, 10:07 AM EDT
Completed No phase listed Observational

Assert-IQ Implantable Cardiac Monitor (ICM) Post Market Study

NCT06172699
View directory record Official record
Conditions
Atrial Fibrillation Paroxysmal, Atrial Fibrillation, Persistent, Cardiac Arrhythmia, Ablation
Interventions
Holter monitoring in patients who have been successfully implanted with an Abbott Assert-IQ ICM device
Device
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
18 Years to 100 Years
Enrollment
151 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
11
States / cities
San Diego, California • Orlando, Florida • Overland Park, Kansas + 8 more
Source: ClinicalTrials.gov public record
Updated May 12, 2026 · Synced Sep 2, 2026, 10:07 AM EDT